1-Methyl-3H-pyrazolo[1,2-a]benzo[1,2,3,4]tetrazin-3-ones. Design, synthesis, and biological activity of new antitumor agents

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 2859-2866

  Almerico, Anna Maria ^a   Mingoia, Francesco ^b   Diana, Patrizia ^a   Barraja, Paola ^a   Lauria, Antonino ^a   Montalbano, Alessandra ^a   Cirrincione, Girolamo ^a   Dattolo, Gaetano ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3H PYRAZOLO[1,2 A]BENZO 1,2,3,4 TETRAZIN 3 ONE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORINE; CYTIDINE DERIVATIVE; RIFAMYCIN; TETRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; KIDNEY CANCER; LEUKEMIA; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PYRAZOLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17444374293     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049075u     Document Type: Article

References (22)

1. (a) Newlands, E. S.; Stevens, M. F. G.; Wedge, S. R.; Wheelhouse, R. T.; Brock, C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rep. 1997, 23, 35-61;
2. (b) Bleehen, N. M.; Newlands, E. S.; Lee, S. M.; Thatcher, N.; Selby, P.; Calvert, A. H.; Rustin, G. J. S.; Brampton, M.; Stevens, M. F. G. Cancer research campaign phase II trial of Temozolomide in metastatic melanoma. J. Clin. Oncol. 1995, 13, 910-913;
3. (c) O'Reilly, S. M.; Newlands, E. S.; Glaser, M. G.; Brampton, M.; Rice-Edwards, J. M.; Illinworth, R. D.; Richards, P. G.; Kennard, C.; Colquhoun, I. R.; Lewis, P.; Stevens, M. F. G. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur. J. Cancer 1993, 29A, 940-942;
4. (d) Newlands, E. S.; Blackledge, G. R. P.; Slack, J. A.; Rustin, G. J. S.; Smith, D. B.; Stuart, N. S. A.; Quarterman, C. P.; Hoffman, R.; Stevens, M. F. G.; Brampton, M. H.; Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 1992, 65, 287-291.
5. (a) Stevens, M. F. G.; Hickman, J. A.; Langdon, S. P.; Chubb, D.; Vickers, L.; Stone, R.; Baig, G.; Goddard, C.; Gibson, N. W.; Slack, J. A.; Newton, C. G.; Lunt, E.; Fizames, C.; Lavelle, F. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,5-tetrazin- 4(3H)-one: (CCRG 81045; M&B 39831) A novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987, 47, 5846-5852;
6. (b) Clark, A. S.; Stevens, M. F. G.; Sansom, C. E.; Schwalbe, C. H. Antitumor imidazotetrazines. Part XXI. Mitozolomide and temozolomide: Probes for the major groove of DNA. Anticancer Drug Des. 1990, 5, 63-68;
7. (c) Lowe, P. R.; Sansom, C. E.; Schwalbe, C. H.; Stevens, M. F. G.; Clark, A. S. Antitumor imidazotetrazines. 25. Crystal structure of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) and structural comparison with the related drugs mitozolomide and DTIC. J. Med. Chem. 1992, 35, 3377-3382;
8. (d) Denny, B. J.; Wheelhouse, R. T.; Stevens, M. F. G.; Tsang, L. L. H.; Slack, J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994, 33, 9045-9051.
9. Diana, P.; Barraja, P.; Lauria, A.; Montalbano, A.; Almerico, A. M.; Dattolo, G.; Cirrincione, G. Pyrrolo[2,1-d][1,2,3,5]tetrazine-4(3H)-ones, a new class of azolotetrazines with potent antitumor activity. Bioorg. Med. Chem. 2003, 11, 2371-2380.
10. Severina, I. S.; Axenova, L. N.; Veselovsky, A. V.; Pyatakova, N. V.; Buneeva, O. A.; Ivanov, A. S.; Medvedev, A. E. Nonselective inhibition of monoamine oxidases a and b by activators of soluble guanylate cyclase. Biochemistry (Translation of Biokhimiya) 2003, 68, 1048-1054.
11. Takamizawa, A.; Hayashi, S. Syntheses of pyrazole derivatives. V. A pyrazole synthesis. Yakugahu Zasshi 1863, 83, 373-377; Chem. Abstr. 1863, 59, 10022e.
12. Takamizawa, A.; Hayashi, S. Syntheses of pyrazole derivatives. V. A pyrazole synthesis. Yakugahu Zasshi 1863, 83, 373-377; Chem. Abstr. 1863, 59, 10022e.
13. Almerico, A. M.; Boulton, A. J. An unusual substitution reaction in a benzotetrazine derivative. J. Chem. Soc. Chem. Commun. 1985, 204-205.
14. Venturello, C.; D'Alosio R. 2-Arylazo-2,5-dimethyl-3-oxo-2,3- dihydrofurans. Useful intermediates in the synthesis of 1-aryl-5-methyl-3- pyrazolones. Synthesis 1979, 283-287.
15. (a) Grever, M. R.; Sherpartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer drug discovery and development program. Semin. Oncol. 1992, 19, 622-638;
16. (b) Monks, A. P.; Scudiero, D. A.; Skehan, P.; Shoemaker, R.; Paull, K. D.; Vistica, D.; Hose, C.; Langley, J.; Croniste, P.; Vaigro-Woiff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. R. Feasibility of a high-flux anticancer drug screen utilizing a derived panel of human tumor cell lines in culture. J. Natl. Cancer Inst. 1991, 83, 757-766;
17. (c) Weinstein, J. N.; Meyers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., Jr.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L, V.; Anderson, N. L.; Boulamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
18. Plowman, J.; Dykes, D. J.; Hollingshead, M.; Simpson-Herren, L.; Alley M. C. In Anticancer Drug Development Guide: pre-clinical screening, clinical trials, and approval; Teicher, B., Ed.; Humana Press: Totowa, NJ, 1997; pp 101-125.
19. Hollingshead, M.; Plowman, J.; Alley M. C.; Mayo J.; Sausville, E. A. The Hollow Fiber Assay. Contrib. Oncol. 1999, 54, 109-120.
20. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubistein, L.; Plowman, J.; Boyd, M. R., J. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. Natl. Cancer Inst. 1989, 81, 1088-1092.
21. available on line at http://spheroid.ncifcrf.gov/default.html and developed according to the following: Rabow, A. A., Shoemaker, R. H., Sausville, E. A., Covell, D. G. Mining the NCI's tumor screening database: Identification of compounds with similar cellular activities. J. Med. Chem. 2002, 45, 818-840.
22. Venturello, C.; D'Alosio R. A new synthesis of 2,5-dimethyl-3(2H)- furanone. Synthesis 1977, 754-755.